Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART.
The impact of proviral DNA reverse transcriptase mutations on virological failure was evaluated in 50 HIV-1 HAART-treated patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor. Neither the M184I/V mutation detected in 12 patients nor stop codons at tryptophane positions detected in 13 patients were associated with virological failure. Stop codons appeared under successful therapy in 12 patients. Their presence should be assessed in studies with higher statistical power.
Makinson
Alain
A
Laboratoire de Virologie, CHU/Hôpital Bichat Claude Bernard, 6 rue Henri Huchard, 75018 Paris, France.
Masquelier
Bernard
B
Taieb
Audrey
A
Peytavin
Gilles
G
Waldner-Combernoux
Anne
A
Collin
Gilles
G
Chêne
Genevieve
G
Brun-Vézinet
Françoise
F
Raffi
François
F
Le Moing
Vincent
V
Leport
Catherine
C
Descamps
Diane
D
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D018388:Codon, Terminator; D015331:Cohort Studies; D004279:DNA, Viral / Q000097:blood; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D011533:Proviruses / Q000235:genetics*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D018388:Codon, Terminator; D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase